

Sameer A Parikh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3938131/sameer-a-parikh-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

157
papers

3,160
citations

28
h-index

54
g-index

164
ext. papers

4,026
ext. citations

4.9
avg, IF

5.23
L-index

#	Paper	IF	Citations
157	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528	59.2	455
156	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016 , 6, 154-65	4.4	269
155	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017 , 129, 3419-3427	2.2	244
154	Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. <i>Mayo Clinic Proceedings</i> , 2014 , 89, 484-92	6.4	173
153	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013 , 162, 774-82	4.5	151
152	Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. <i>Blood</i> , 2017 , 129, 553-560	2.2	126
151	How we treat Richter syndrome. <i>Blood</i> , 2014 , 123, 1647-57	2.2	116
150	A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults. <i>Cancer</i> , 2017 , 123, 3229-3240	6.4	97
149	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1630-1639	1.9	71
148	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015 , 125, 1676-8	2.2	57
147	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 334-8	7.1	56
146	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. <i>Haematologica</i> , 2015 , 100, 1180-8	6.6	53
145	Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <i>Blood</i> , 2016 , 127, 1752-60	2.2	53
144	Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia. <i>Haematologica</i> , 2016 , 101, 458-65	6.6	51
143	Prognostic factors and risk stratification in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016 , 43, 233-40	5.5	48
142	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015 , 121, 2883-91	6.4	47
141	Chronic lymphocytic leukemia in young (≤55 years) patients: a comprehensive analysis of prognostic factors and outcomes. <i>Haematologica</i> , 2014 , 99, 140-7	6.6	47

140	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. <i>Haematologica</i> , 2020 , 105, 348-357	6.6	46
139	Chronic lymphocytic leukemia treatment algorithm 2018. <i>Blood Cancer Journal</i> , 2018 , 8, 93	7	46
138	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020 , 135, 1859-1869	2.2	45
137	Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. <i>Blood</i> , 2016 , 128, 2093-2095	2.2	42
136	Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017 , 178, 394-402	4.5	37
135	Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012 , 87, 610-9	7.1	37
134	PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 843-854	6.7	35
133	NUT midline carcinoma: an aggressive intrathoracic neoplasm. <i>Journal of Thoracic Oncology</i> , 2013 , 8, 1335-8	8.9	32
132	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020 , 105, 765-773	6.6	31
131	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1376-1383	1.9	30
130	Risk factors for Richter syndrome in chronic lymphocytic leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014 , 9, 294-9	4.4	29
129	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2712-2719	1.9	28
128	A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2017 , 12, 29-38	4.4	26
127	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018 , 183, 421-427	4.5	25
126	Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1973-1976	1.9	24
125	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.5	23
124	Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013 , 88, 967-74	7.1	22
123	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020 , 9, 3390-3399	4.8	19

122	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017 , 178, 99-105	4.5	15
121	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. <i>Lancet Haematology</i> , 2016 , 3, e407-14	14.6	15
120	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 2935-2935	2.2	15
119	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015 , 126, 834-834	2.2	15
118	Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2019 , 33, 638-652	10.7	15
117	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. <i>Blood</i> , 2018 , 132, 6-6	2.2	13
116	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. <i>Leukemia</i> , 2021 , 35, 1864-1872	10.7	13
115	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). <i>Vaccine</i> , 2021 , 39, 1122-1130	4.1	13
114	Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases. <i>American Journal of Hematology</i> , 2018 , 93, E35-E37	7.1	12
113	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. <i>Molecular Therapy</i> , 2021 , 29, 1529-1540	11.7	12
112	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020 , 105, 2675-2678	6.6	11
111	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2383-2388	1.9	11
110	Characterization of a cryptic rearrangement in a case of mantle cell lymphoma with negative FISH studies. <i>Blood Advances</i> , 2019 , 3, 1298-1302	7.8	11
109	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 338-345	7.1	11
108	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. <i>Leukemia</i> , 2019 , 33, 2111-2115	10.7	10
107	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018 , 103, e237-e240	6.6	9
106	Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 337-349	2.8	9
105	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018 , 93, E216-E219	7.1	9

104	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 865-865	2.2	9
103	Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 720-9	0.6	9
102	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e22-e25	6.6	8
101	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. <i>Leukemia</i> , 2018 , 32, 1869-1873	10.7	8
100	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <i>Leukemia and Lymphoma</i> , 2019 , 60, 559-561	1.9	8
99	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017 , 92, 1362-1369	7.1	8
98	Philadelphia chromosome-negative acute lymphoblastic leukemia: therapies under development. <i>Future Oncology</i> , 2014 , 10, 2201-12	3.6	7
97	Primary Analysis of Anti-CD19 Tafasitamab (MOR208) Treatment in Combination with Idelalisib or Venetoclax in R/R CLL Patients Who Failed Prior BTK Inhibitor Therapy (COSMOS Trial). <i>Blood</i> , 2019 , 134, 1754-1754	2.2	7
96	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 717-717	2.2	7
95	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016 , 128, 4392-4392	2.2	7
94	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021 , 106, 2845-2852	6.6	7
93	Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. <i>Blood Advances</i> , 2020 , 4, 4508-4511	7.8	7
92	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021 , 35, 239-244	10.7	7
91	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021 , 100, 143-155	3	7
90	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1592-1600	1.9	6
89	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020 , 95, 906-917	7.1	6
88	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020 , 105, 1613-1620	6.6	6
87	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1752-1755	1.9	5

86	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carc. <i>Blood</i> , 2019 , 134, 3868-3868	2.2	5
85	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 2950-2950	2.2	5
84	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020 , 95, E57-E60	7.1	5
83	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020 , 25, 974-980	5.7	5
82	Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.. <i>Blood</i> , 2022 ,	2.2	4
81	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2021 , 97, 90	7.1	4
80	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021 , 138, 149-159	2.2	4
79	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021 , 137, 2046-2056	2.2	4
78	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021 , 11, 86	7	4
77	Cryptococcus neoformans infections in patients with lymphoproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2019 , 60, 920-926	1.9	4
76	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 17	22.4	4
75	Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2287-2296	1.9	4
74	Single-Antibody Evaluation of T-Cell Receptor α Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 139-148	1.9	4
73	Predicting Time to First Treatment in Chronic Lymphocytic Leukemia Using Machine Learning Survival and Classification Methods 2018 ,		3
72	Oral capecitabine to prevent recurrent cutaneous squamous cell carcinoma in a lung transplant recipient. <i>International Journal of Dermatology</i> , 2015 , 54, e358-60	1.7	3
71	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020 , 136, 47-48	2.2	3
70	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
69	A Multicenter, Retrospective Study of Accelerated Venetoclax Ramp-up in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 51-52	2.2	3

68	Analysis of Serum Ferritin Levels As a Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) in Hospitalized Adult Patients. <i>Blood</i> , 2015 , 126, 1014-1014	2.2	3
67	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. <i>Blood</i> , 2015 , 126, 4169-4169	2.2	3
66	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017 , 130, 831-831 ²	2.2	3
65	Chronic lymphocytic leukemia B-cell-derived TNF α impairs bone marrow myelopoiesis. <i>IScience</i> , 2021 , 24, 101994	6.1	3
64	Early intervention in asymptomatic chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19, 92-103	0.6	3
63	Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy. <i>Blood</i> , 2018 , 132, 4433-4433	2.2	2
62	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019 , 134, 3050-3050	2.2	2
61	Multiple B cell malignancies in patients with chronic lymphocytic leukemia: epidemiology, pathology, and clinical implications. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1037-1051	1.9	2
60	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1581-1589	4.5	2
59	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. <i>Cancer Immunology Research</i> , 2021 , 9, 1035-1046	12.5	2
58	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. <i>Leukemia</i> , 2020 , 34, 1979-1983	10.7	1
57	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
56	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
55	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 16-17	2.2	1
54	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
53	A multicenter, retrospective study of accelerated venetoclax ramp-up in patients with relapsed/refractory chronic lymphocytic leukemia.. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
52	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022 , 12, 18	7	1
51	CLL update 2022: A continuing evolution in care.. <i>Blood Reviews</i> , 2022 , 100930	11.1	1

50	Calm before the Storm.. <i>New England Journal of Medicine</i> , 2022 , 386, 479-485	59.2	1
49	Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. <i>Blood</i> , 2018 , 132, 728-728	2.2	1
48	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. <i>Blood</i> , 2019 , 134, 53-53	2.2	1
47	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019 , 134, 679-679	2.2	1
46	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
45	Central Nervous System Involvement By Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2919-2919	2.2	1
44	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. <i>Blood</i> , 2018 , 132, 586-586	2.2	1
43	Novel Mutations in NOTCH and Altered Wnt/ β Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016 , 128, 4103-4103	2.2	1
42	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016 , 128, 5592-5592	2.2	1
41	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 47	7	1
40	The prognostic significance of del6q23 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E203-E206	7.1	1
39	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021 , 137, 513-523	2.2	1
38	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2021 ,	10.7	1
37	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021 , 138, 906-906	2.2	0
36	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2021 ,	1.3	0
35	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021 , 11, 140	7	0
34	Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1289-1301	1.9	0
33	Isolated anemia in patients with large granular lymphocytic leukemia (LGLL).. <i>Blood Cancer Journal</i> , 2022 , 12, 30	7	0

32	Secondary Hemophagocytic Syndrome Associated with Richter Transformation in Chronic Lymphocytic Leukemia. <i>Case Reports in Hematology</i> , 2014 , 2014, 287479	0.7
31	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020 , 136, 35-36	2.2
30	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020 , 136, 26-27	2.2
29	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 10-12	2.2
28	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020 , 136, 28-29	2.2
27	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020 , 136, 3-4	2.2
26	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2
25	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 1-1	2.2
24	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 50-51	2.2
23	Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2021 , 138, 4677-4677	2.2
22	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021 , 138, 2777-2777	2.2
21	B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2021 , 138, 3313-3313	2.2
20	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018 , 132, 3116-3116	2.2
19	Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions. <i>Blood</i> , 2018 , 132, 1865-1865	2.2
18	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018 , 132, 1857-1857	2.2
17	Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment. <i>Blood</i> , 2018 , 132, 3132-3132	2.2
16	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. <i>Blood</i> , 2018 , 132, 4399-4399	2.2
15	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018 , 132, 5538-5538	2.2

14	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019 , 134, 3022-3022	2.2
13	A Role for TNF- α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. <i>Blood</i> , 2019 , 134, 4276-4276	2.2
12	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019 , 134, 852-852	2.2
11	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019 , 134, 3037-3037	2.2
10	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Blood</i> , 2015 , 126, 481-481	2.2
9	National Epidemiology of Inpatient Venous Thromboembolism in Patients with Hematologic Malignancies in United States from 1993 to 2012. <i>Blood</i> , 2015 , 126, 630-630	2.2
8	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2926-2926	2.2
7	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016 , 128, 2020-2020	2.2
6	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016 , 128, 5585-5585	2.2
5	A Distributed International Patient Data Registry for Hairy Cell Leukemia. <i>Blood</i> , 2016 , 128, 5986-5986	2.2
4	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016 , 128, 5575-5575	2.2
3	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016 , 128, 3228-3228	2.2
2	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. <i>Journal of Hematopathology</i> , 2020 , 13, 221-229	0.4
1	Upregulation of AXL and Eatenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. <i>Blood Cancer Journal</i> , 2021 , 11, 37	7